Our initial focus lies on some of the most aggressive cancer types
DIPG, Ewing's Sarcoma, Osteoscarcoma, Medulloblastoma, Neuroblastoma, Rhabdomyoscarcoma and Leukemias (ALL and AML)) are the initial cancer types we will focus on.
We believe that access to accurate information about each type of childhood tumor from identification of new oncogenic targets will facilitate the development of new drugs specifically for children with cancer and ensure more effective cancer treatments.
Repurposing reduces the risks, time and cost of drug development
Extends the value and life cycle of existing drugs.
Fits naturally within a risk reduction model since repurposing begins with approved or late stage development compounds with established safety and bioavailability profiles that can also enter clinical testing rapidly.